RA
VTVT icon

Royce & Associates’s vTv Therapeutics VTVT Stock Holding History

Royce & Associates’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-9,075
Closed -$1.48M – 1260
2018
Q1 		$1.48M Buy
9,075
+3,450
+61% +$845K 0.01% 912
2017
Q4 		$1.35M Buy
+5,625
New +$1.26M 0.01% 918

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Royce & Associates's VTVT Position: Q2 2018 in Review

Royce & Associates sold out of vTv Therapeutics (VTVT) in Q2 2018, closing a stake of 9,075 shares — an estimated $1.48M sold.

Royce & Associates first reported a position in VTVT in Q4 2017 and held it in 2 quarters. The position peaked at $1.48M in Q1 2018. 27 funds tracked by Wall St. Rank hold VTVT as of Q2 2018.

  • Royce & Associates reported no remaining vTv Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Royce & Associates sold 9,075 vTv Therapeutics shares in Q2 2018, an estimated $1.48M.
  • Royce & Associates first reported a position in vTv Therapeutics in Q4 2017 and held it in 2 quarters.
  • Royce & Associates's vTv Therapeutics position peaked at $1.48M in Q1 2018.
  • 27 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2018.

Based on Royce & Associates's 13F filing for Q2 2018, filed 9 Aug 2018.